Granules India’s Unit V facility in Visakhapatnam that manufactures APIs and formulations of oncology and non-oncology merchandise
| Photo Credit: Special association
Drugmaker Granules India’s Unit V manufacturing facility in Visakhapatnam has accomplished an U.S. Food and Drug Administration inspection.
It was a pre-approval inspection (PAI) and cGMP audit for APIs and formulations for oncology and non-oncology merchandise. The unit efficiently accomplished the U.S. FDA inspection, performed from April 8-12, ensuing in zero Form 483 observations, the corporate mentioned. “Proud to reiterate that our focus on high-quality standards is comparable to the best global benchmarks as we receive zero observations from U.S. FDA audit,” CMD Krishna Prasad Chigurupati mentioned in a launch on Saturday.
